Human MLH1 protein participates in genomic damage checkpoint signaling in response to DNA interstrand crosslinks, while MSH2 functions in DNA repair.
DNA interstrand crosslinks (ICLs) are among the most toxic types of damage to a cell. For this reason, many ICL-inducing agents are effective therapeutic agents. For example, cisplatin and nitrogen mustards are used for treating cancer and psoralen plus UVA (PUVA) is useful for treating psoriasis. However, repair mechanisms for ICLs in the human genome are not clearly defined. Previously, we have shown that MSH2, the common subunit of the human MutSalpha and MutSbeta mismatch recognition complexes, plays a role in the error-free repair of psoralen ICLs. We hypothesized that MLH1, the common subunit of human MutL complexes, is also involved in the cellular response to psoralen ICLs. Surprisingly, we instead found that MLH1-deficient human cells are more resistant to psoralen ICLs, in contrast to the sensitivity to these lesions displayed by MSH2-deficient cells. Apoptosis was not as efficiently induced by psoralen ICLs in MLH1-deficient cells as in MLH1-proficient cells as determined by caspase-3/7 activity and binding of annexin V. Strikingly, CHK2 phosphorylation was undetectable in MLH1-deficient cells, and phosphorylation of CHK1 was reduced after PUVA treatment, indicating that MLH1 is involved in signaling psoralen ICL-induced checkpoint activation. Psoralen ICLs can result in mutations near the crosslinked sites; however, MLH1 function was not required for the mutagenic repair of these lesions, and so its signaling function appears to have a role in maintaining genomic stability following exposure to ICL-induced DNA damage. Distinguishing the genetic status of MMR-deficient tumors as MSH2-deficient or MLH1-deficient is thus potentially important in predicting the efficacy of treatment with psoralen and perhaps with other ICL-inducing agents.
Wu
Qi
Q
Department of Carcinogenesis, University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, Texas, United States of America.
Vasquez
Karen M
KM
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D003432:Cross-Linking Reagents / Q000633:toxicity; D004247:DNA / Q000378:metabolism; D004249:DNA Damage; D004260:DNA Repair / Q000502:physiology*; D005363:Ficusin / Q000633:toxicity; D018816:Genes, cdc / Q000502:physiology; D015894:Genome, Human; D006801:Humans; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein / Q000378:metabolism*; D009154:Mutation; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics
D048868:Adaptor Proteins, Signal Transducing; D003432:Cross-Linking Reagents; C501486:MLH1 protein, human; D009687:Nuclear Proteins; D004247:DNA; C497172:MSH2 protein, human; D000070957:MutL Protein Homolog 1; D051718:MutS Homolog 2 Protein; D005363:Ficusin
J Biol Chem. 2006 Oct 13;281(41):30305-9
16905530
Gastroenterology. 2005 Aug;129(2):537-49
16083711
Mutat Res. 1983 Dec;124(3-4):287-97
6656829
DNA Repair (Amst). 2005 Aug 15;4(9):983-93
15996534
Carcinogenesis. 1999 May;20(5):799-804
10334196
Natl Cancer Inst Monogr. 1984 Dec;66:127-36
6397690
Nucleic Acids Res. 1999 Feb 15;27(4):1176-81
9927753
Carcinogenesis. 1996 Sep;17(9):2085-8
8824540
Clin Cancer Res. 1997 Oct;3(10):1763-7
9815561
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):5848-53
11972036
Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6443-7
8692834
Genes Dev. 2004 Jun 1;18(11):1331-44
15175264
Cancer Res. 1996 Nov 1;56(21):4881-6
8895738
Nucleic Acids Res. 2005 May 24;33(9):2993-3001
15914671
Cancer Res. 1995 Sep 1;55(17):3721-5
7641183
Oncogene. 2003 Sep 18;22(40):6119-28
13679850
Lancet Oncol. 2001 Aug;2(8):483-90
11905724
Mol Biol Cell. 2005 Mar;16(3):1513-26
15647386
Mol Cell. 1999 Sep;4(3):439-44
10518225
Q Rev Biophys. 2002 Feb;35(1):89-107
11997982
Carcinogenesis. 2001 Dec;22(12):1931-7
11751422
Nat Genet. 2003 Jan;33(1):80-4
12447371
Mol Cell Biol. 2002 Apr;22(7):2388-97
11884621
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10764-9
10485900
J Biol Chem. 2001 Aug 24;276(34):31551-60
11390398
Mol Cell Biol. 2001 Feb;21(3):713-20
11154259
Eur J Biochem. 1996 Jun 1;238(2):297-307
8681938
EMBO Rep. 2005 Jun;6(6):551-7
15891767
Science. 1998 Dec 4;282(5395):1893-7
9836640
Carcinogenesis. 1999 Dec;20(12):2317-26
10590226
Cancer Res. 1997 Sep 1;57(17):3784-91
9288788
Biochem Pharmacol. 1992 Mar 3;43(5):1159-63
1532492
Annu Rev Biochem. 1996;65:101-33
8811176
Dermatol Clin. 1998 Apr;16(2):227-34
9589196
Biochem Biophys Res Commun. 2004 May 21;318(1):297-302
15110787
Biochemistry. 1996 Aug 20;35(33):10712-9
8718860
Nucleic Acids Res. 1997 Feb 1;25(3):491-6
9016586
EMBO J. 2003 May 1;22(9):2245-54
12727890
Mol Cell. 2006 May 19;22(4):501-10
16713580
J Biol Chem. 1999 Jun 11;274(24):16894-900
10358035
Nat Rev Mol Cell Biol. 2006 May;7(5):335-46
16612326
Chem Rev. 2006 Feb;106(2):302-23
16464007
J Biol Chem. 2003 Jun 6;278(23):21267-75
12654906
Cancer Res. 1997 Nov 15;57(22):5143-7
9371516
Mol Cell Biol. 2000 Nov;20(21):8283-9
11027296
EMBO J. 2004 Mar 10;23(5):1178-87
14988723
J Biol Chem. 2002 Mar 8;277(10):8260-6
11756455
Mol Carcinog. 2004 Jun;40(2):122-33
15170817
Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5602-6
2062839
Mol Cell Biol. 1999 Dec;19(12):8292-301
10567554
Annu Rev Biochem. 2004;73:39-85
15189136
Biochemistry. 2005 Mar 22;44(11):4188-95
15766246
Mutat Res. 1989 May;217(3):193-201
2541332